The Tissue Banking and Analysis Center (TBAC), in collaboration with US Oncology and AmeriPath, one of the largest networks of pathologists engaged in cancer diagnosis, will provide unprecedented access to tissue samples, clinical trial design, biomarker development and esoteric testing under the guidance of top scientists from government and industry.
The development of TBAC’s large centralized tissue bank and analysis services allows for the rapid standardized collection and analysis of a large repository of data, bio-specimens and clinical information that helps researchers improve the design of future cancer research studies and allow the selection of specific trial participants based on their molecular profile.
Fewer patients may be required to adequately test the efficacy of new therapies and the result should be an acceleration of the research necessary to make personalized therapies a reality.
“This venture will fill a huge unmet need in cancer drug development and over time, it will enable more personalized therapies and enable better treatment accuracy and outcomes for cancer patients across the nation,” said Dr Atul Dhir, president of the Cancer Information Research Group for US Oncology and board member of TBAC.